Previous 10 | Next 10 |
home / stock / dmt:cc / dmt:cc news
• Multiple clinical milestones achieved including the first proof-of-concept for DMT-based therapies from a blinded placebo-controlled study • Preliminary findings from SPL028 Phase I clinical trial support target drug profile • Operational efficiencies unde...
LONDON, May 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces an update...
LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce th...
LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces positiv...
LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, today announces that it...
-Patients’ self-reported depression and wellbeing scores corroborate MADRS efficacy data -Statistically significant improvement in anxiety symptoms offers potential in new indications beyond depression LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT)...
LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce ...
SPL028 is a proprietary deuterated DMT candidate with multi-layered IP protection Phase I study will compare two routes of SPL028 administration; intravenous and intramuscular LONDON, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “...
New United States patents will provide further support for the Company’s proprietary position in a key jurisdiction United States grants will bring the Company’s total to 16 granted patents and over 90 applications pending LONDON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sm...
Positive top-line results from Phase IIa trial of SPL026 in Major Depressive Disorder New SPL026 trials underway and screening commenced in the first in-human study of SPL028 LONDON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the ...
News, Short Squeeze, Breakout and More Instantly...
2024-03-27 17:08:02 ET The world is facing a mental health crisis. Today, one in six individuals are likely to suffer from an episode of major depression during their lifetime that could significantly impact their relationships, work and health. Add to that the substantial negative impact t...
2024-03-27 17:08:02 ET Help for mental health sufferers Small Pharma is a neuropharmaceutical company. They specialize in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into DMT-assiste...
TSX Venture Exchange Stock Maintenance Bulletins Canada NewsWire VANCOUVER, BC , Oct. 24, 2023 /CNW/ - TSX VENTURE COMPANIES MINTO METALS CORP. ("MNTO") BULLETIN TYPE: Delist BULLETIN DATE: October 24, 2023 T...